• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

    57.95 -0.02 (-0.03%)
    Streaming Delayed Price Updated: 11:36 AM EST, Feb 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about RAPT Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗
    This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗
    RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗
    This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology. 
    Via The Motley Fool
    Topics Regulatory Compliance
    RAPT THERAPEUTICS INC (NASDAQ:RAPT) Shows High Technical and Pattern Scores Ahead of Potential Breakout ↗
    Via Chartmill
    News headline image
    Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations
    Shareholders should contact the firm as there may be limited time to enforce your rights. 
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC Reminds Shareholders of JHG, FOLD, RAPT of the Firm’s Investigations
    Shareholders should contact the firm as there may be limited time to enforce your rights 
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
    Shareholders should contact the firm as there may be limited time to enforce your rights 
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights
    Shareholders should contact the firm as there may be limited time to enforce your rights 
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    The Great Consolidation: US M&A Values Double as AI and Bio-Pharma Spark $2 Trillion Surge
    As of January 26, 2026, the American corporate landscape is undergoing its most radical transformation in a generation. Following a two-year period of high-interest-rate hibernation, the United States... 
    Via MarketMinute
    Topics Artificial Intelligence Economy
    News headline image
    Halper Sadeh LLC Encourages NATH, RAPT, FONR Shareholders to Contact the Firm to Discuss Their Rights
    Shareholders should contact the firm as there may be limited time to enforce your rights 
    From Halper Sadeh LLC
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    Why Rapt Therapeutics Stock Soared Today ↗
    A global healthcare giant wants to acquire the biotech's promising development program. 
    Via The Motley Fool
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Here are the top movers in Tuesday's session. ↗
    Via Chartmill
    Tuesday's session: top gainers and losers ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics
    In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion.... 
    Via MarketMinute
    Topics Intellectual Property
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    RAPT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of RAPT Therapeutics, Inc. is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    News headline image
    Why Did RAPT Stock Surge 63% In Pre-Market Today? ↗
    GSK will acquire RAPT for $58.00 per share in cash, a 65.2% premium over Friday’s closing price of $35.1. 
    Via Stocktwits
    News headline image
    RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗
    A full exit during a volatile stretch raises a sharper question than timing alone. 
    Via The Motley Fool
    News headline image
    Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
    The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
    Via MarketMinute
    Topics Artificial Intelligence Intellectual Property
    News headline image
    RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
    From RAPT Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.